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Abstract. An important component of the pathogenic process
of multiple sclerosis (MS) is the blood-brain barrier (BBB)
damage. We recently set an in vitro model of BBB, based on
a three-cell-type co-culture system, in which rat neurons and
astrocytes synergistically induce brain capillary endothelial
cells to form a monolayer with permeability properties
resembling those of the physiological BBB. Herein we report
that the serum from patients with secondary progressive
multiple sclerosis (SPMS) has a damaging effect on isolated
neurons. This finding suggests that neuronal damaging in MS
could be a primary event and not only secondary to myelin
damage, as generally assumed. SPMS serum affects the
permeability of the BBB model, as indicated by the decrease
of the transendothelial electrical resistance (TEER).
Moreover, as shown by both immunofluorescence and
Western blot analyses, BBB breaking is accompanied by a
decrease of the synthesis as well as the peripheral
localization of occludin, a structural protein of the tight
junctions that are responsible for BBB properties.
Introduction
Multiple sclerosis (MS) is a neurodegenerative disease
characterized by focal inflammatory demyelination and glial
scar formation. The pathogenic mechanism of MS is multi-
factorial (1,2) and heterogeneous, both in terms of clinical
course and neuropathological appearance (3). However, it is
accepted to consist of inflammatory and neurodegenerative
phases (4), where demyelination should produce partially
reversible clinical deficits that can remit, due to limited
remyelination, while axonal degeneration produces permanent
non-remitting clinical damage (5).
It is also assumed that the nervous system inflammation is
initiated by autoreactive, myelin-specific T cells that permeate
the blood-brain barrier and trigger a series of events leading
to destruction of the myelin sheet (6). According to this view,
axonal loss is considered secondary to inflammation and
demyelination. However, it is becoming increasingly evident
that extensive axonal damage already occurs at early stages
of MS (7-9): axons could be sensitive to proteases, inflam-
matory cytokines and other molecules, produced by either
activated immune cells or glial cells (10).
It has been found that neurofilament components (11), as
well as other proteins of the cytoskeleton are costantly
modified in MS patients during the entire course of the disease,
thus confirming continuous axonal damage.
Although the exact cause of early axonal damage in MS
remains elusive, it has been suggested that unknown factors
present in the cerebrospinal fluid (CSF) from MS patients
can induce neuronal apoptosis in cultured neurons (12,13). In
addition, neuronal apoptosis has been described in both cortical
MS lesions (14) and in a rat model of MS [experimental
autoimmune encephalomyelitis, EAE (15)].
Disruption of the blood-brain barrier is a hallmark of MS
pathogenesis, possibly due to alterations of the tight junctions
(TJs) that normally seal brain capillary endothelial cells
together, thus impeding the paracellular flux of molecules
across the endothelial cell layer. It has been recently reported
that, although the highest level of disruption (affecting 40%
of vessels) can be observed in active lesions, TJ disruption is
also apparent in inactive lesions (23% of vessels). Moreover,
TJ disruption is accompanied by serum protein leakage
across the BBB (16). A central role in BBB disruption might
be played by astrocytes. Immunohistochemical analyses have
revealed that several hypertrophic astrocytes are present at
the rim of chronic active lesions and that these astrocytes
produce chemokines, such as monocyte chemoattractant
protein-1 (MCP-1) and interferon Á-inducible protein-10
(IP-10), as well as their receptors, CCR2 and CXCR3 (17).
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Factors produced by astrocytes (18) might induce migration/
activation of microglia and/or macrophages, and also lead to
BBB disruption.
In this study, we report that in the serum from patients
with secondary-progressive multiple sclerosis factors are
present that induce neuronal cell death and cause alteration of
permeability in a BBB model system.
Materials and methods
Patient recruitment and informed agreement. After accurate
visiting and diagnosis, or control visit, the patients were
informed of the ongoing research which was aimed at
understanding the cellular and molecular mechanisms that
underlie the pathology. Accurate explanations and further
information were also given about the forms to be filled in and
signed, in case of agreement to contribute to the research. All
the procedures were done according to the Decree Law No.
196/03 (Arts. 7 and 13) that concerns protection of patients'
privacy in the data processing and according to the World
Medical Association Declaration of Helsinki.
Animals. Wistar rats (Stefano Morini, San Polo d'Enza, Italy)
were housed in the institutional animal care facility of the
Department of ‘Biologia Cellulare e Sviluppo’ (University of
Palermo, Palermo, Italy), under direction of a licensed
veterinary who approved the protocols. Procedures involving
animals were conducted according to the European Community
Council Directive 86/609, OJL 358 1, December 12, 1987. The
number of animals used, as well as their suffering, has been
reduced as much as possible. All protocols have been approved
by the Ethics Committee of the University of Palermo.
Cell culture treatment and vitality assay. Neurons were
purified from fetal rat cortices at the 16th day of gestation and
cultured in serum-free Maat medium (MM) (19), on laminin
(2.5 μg/cm2), as previously described (20). Astrocytes were
purified from brain cortices of 2-day-old rats, as described
by Cole and de Vellis (21), and cultured on fibronectin, in
DME/Ham's F12 (2:1), supplemented with 10% (v/v) heat-
inactivated fetal calf serum, up to half-confluence. RBE4.B
immortalized rat brain microvessel cells (kind gift of Dr F.
Roux, under the permission of Neurotech SA, Orsay, France)
(22) were plated on collagen I (2 mg/cm2) and maintained in
DME-Ham's F-12 (2:1), supplemented with 10% (v/v) heat-
inactivated fetal calf serum, 2 mM glutamine, up to half-
confluence.
In order to set the BBB in vitro model, we used the
transwell system described elsewhere (23-25). Briefly, neurons
were cultured on laminin at the bottom of the wells of the
companion plates, and fed with MM for 5 days. Afterwards,
the porous inserts, on which astrocytes (adhering to the outer
side of the porous membrane, on fibronectin) had been
cultured for 4 h, were wedged into the wells. After 2 more
days, RBE4.B brain capillary endothelial cells (BCECs) were
plated onto the inner surface of the insert membrane, on
collagen IV. The entire system was then fed with MM for 5
days, before treatment.
For the analysis of the effects of MS patient serum,
neuronal cell cultures were treated since the beginning with
either control sera from healthy volunteers or with sera from
patients with secondary progressive multiple sclerosis (SPMS),
at a final concentration of 10% (v/v). The BBB three-cell
type model was instead treated with 10% (v/v) serum for 24 h
only.
Cell death was analyzed by staining the cells with a mixture
of the fluorescent DNA-binding dyes, acridine orange (AO)
and ethidium bromide (EB), each at a concentration of 100 μg/
ml in PBS, as previously described (26).
Permeation experiments across the BCEC monolayer
were started by substituting the feeding medium in the upper
(donor) chamber with an identical volume of MM, in which
serum (from SPMS patients or healthy volunteers) had been
dissolved, at the final concentration of 10% (v/v).
After 24 h, the medium in both chambers was substituted
with an equal volume of fresh MM, and the variation of
transendothelial electrical resistance (TEER) was monitored,
as described below. 
Immunofluorescence. Cells were fixed with 96% ethanol, on
ice, for 10 min and permeabilized for 5 min with 0.1% Triton
X-100, in PBS. Afterwards, they were incubated with goat
polyclonal anti-occludin N19 antibodies (Santa Cruz, CA,
USA). The secondary antibodies were anti-goat IgGs,
conjugated to fluoresceine (Santa Cruz). The samples were
also stained for DNA by treating with Vectashield mounting
medium for fluorescence, containing 4'-,6-diamino-2-phenyl-
indole (DAPI; Vector Laboratories, Youngstown, OH, USA).
Cells were finally observed with an Olympus BX-50
microscope (Olympus Italia s.r.l., Segrate, Italy), equipped
with Vario Cam B/W camera (Nikon Instruments s.p.a.,
Calenzano, Italy).
Western blot analyses. Cells were homogenized in homo-
genization buffer (0.32 M sucrose; 50 mM sodium phosphate
buffer, pH 6.5; 50 mM KCl, 0.5 mM spermine; 0.15 mM
spermidine; 2 mM EDTA, and 0.15 mM EGTA), containing
the protease inhibitors aprotinin (2 μg/ml), antipain (2 μg/ml),
leupeptin (2 μg/ml), pepstatin A (2 μg/ml), benzamidine
(1.0 mM) and phenylmethylsulfonyl fluoride (1.0 mM), all
purchased from Sigma-Aldrich. Proteins (20 μg of total cell
extracts) were separated by electrophoresis on denaturing 10%
polyacrylamide slab gels (SDS-PAGE) and immunoblotted as
described elsewhere (27). The membranes were immuno-
stained with goat polyclonal anti-occludin N19 antibodies
(Santa Cruz).
TEER measurement. TEER measurements were done by using
an EVOM epithelial voltom meter, equipped with an STX2
electrode (World Precision Instruments, Berlin). In parallel
with sample measurements, we also recorded the resistance
of inserts bearing only the collagen IV and fibronectin
substrata (blank values). The average of the blank values was
subtracted from the resistance reading across the BCEC
layer, in order to obtain the true resistance due to BCECs.
Results
We previously found that both neurons (24,27,28) and
astrocytes (23,24) influence the ability of endothelial cells to
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form a barrier with properties resembling those of BBB. In
the present study, we used an already described BBB in vitro
model (23,24) to investigate whether the serum from patients
with secondary progressive multiple sclerosis (SPMS) (29)
caused any alteration of the neuronal vitality and morphology,
and/or any BBB damage. We analyzed first whether a 24 h
treatment with SPMS serum (10% in MM) might induce
neuronal death. Neurons were stained with a mixture of
acridine orange (AO) and ethidium bromide (EO). The
differential uptake of these two dyes allows identification of
viable and non-viable cells by fluorescence microscopy:
normal nuclei in alive cells appear bright green, while
apoptotic nuclei in dead cells appear bright orange/red and,
in many cases, even fragmented into apoptotic bodies. As
shown in Fig. 1, neurons treated with serum from healthy
volonteers have green nuclei (Fig. 1a and a*), while cells
treated with SPMS serum are clearly damaged (Fig. 1b and b*).
Moreover, phase-contrast microscopy showed that
morphology of neurites was also affected by treatment with
SPMS (Fig. 2a*), respect to control cells (Fig. 2a). The most
peculiar observation was the increased diameter of the bundles
of neurites, which appear thicker in SPMS-treated cells
(Fig. 2a*).
Next, we investigated the possibility that the SPMS serum
induces damage of the in vitro BBB model. We used a three
cell type-coculture system (23,24), that includes neurons,
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Figure 1. Induction of neuronal cell death by serum from secondary-progressive multiple sclerosis patients. Neurons were cultured for 5 days in Maat medium,
containing 10% (v/v) serum from either healthy volunteers (a and a*) or SPMS patients (b and b*). At the end of treatment, cells were stained with a
combination of the fluorescent DNA-binding dyes acridine orange and ethidium bromide, 100 μg each/ml in PBS. Cells were observed in an Olympus BX-50
microscope, equipped with Vario Cam B/W camera.
Figure 2. Phase-contrast microscopy recording of the morphological
appearance of neurons, cultured for 15 days, in Maat Medium containing
10% (v/v) serum from either healthy volunteers (a) or SPMS patients (a*).
The arrows point to abnormally thick bundles of neurites.
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astrocytes and brain capillary endothelial cells (BCECs).
BCECs were cultured inside the inserts, on collagen IV, in
the presence of both neurons and astrocytes, and then treated
with either serum from healthy controls (Fig. 3a), or SPMS
serum (Fig. 3b), for 24 h. Then cells were immunostained for
occludin, one of the main structural proteins of the tight
junctions (TJs), that seal endothelial cells together in the
physiological BBB. As shown in Fig. 3, SPSM serum-treated
cells (Fig. 3b), showed a severe decrease of peripherical
immunofluorescent occludin, compared to cells treated with
control serum (Fig. 3a). In agreement with this observation,
Western blot analysis of BCECs, treated as described above,
showed that the two main bands expected for occludin (60-
and 48-kDa, respectively) (24,27,30,31) disappeared in
SPMS-treated cells (Fig. 4).
Finally, the whole BBB in vitro model was tested by
measuring the transendothelial electrical resistance, in each
condition. We found that the treatment with SPMS serum
caused a significant (p<0.005) decrease of TEER (Fig. 5).
Discussion
In this study, we report that serum from secondary-progressive
multiple sclerosis patients induces cell death in cultured
neurons and causes a severe decrease of the transendothelial
electrical resistance in a BBB in vitro model.
The studies concerning neurons themselves clearly showed
a profound effect on cell vitality. We observed that the
neurite morphology was severely changed; the neurite
bundles appeared much ticker in the SPMS-treated neurons,
thus suggesting an alteration of the concentration and/or
localization of certain factor(s) involved in bundling. Even if
we cannot yet say which factors might be involved, the effect
is quite evident. An effect of the SPMS serum on the
permeability of an in vitro model of BBB was also found.
We previously reported that RBE4.B brain capillary endo-
thelial cells (BCECs), cultured on collagen IV, form a barrier
with BBB permeability properties, when co-cultured with
astrocytes and/or neurons. Herein, we used this model to test
the effects of SPMS serum. We chose two criteria to evaluate
possible BBB damage: i) expression and peripheral locali-
zation of occludin. This protein has been reported to be a
marker of TJ maturation, and TJs are of the most importance
for the establishment of the BBB function, because they seal
cells together, thus abolishing the paracellular flux of molecules
and ions; ii) the transendothelial electrical resistance (TEER),
measured across the BCEC monolayer, after treatment with
sera from either healthy volunteers or SPMS patients. TEER
is a consequence of the existence of a tissue barrier, which
opposes the free exchange of ions across a given epithelium/
endothelium.
According to both criteria, a BBB alteration was evident:
i) occludin almost disappeared, as concluded on the basis of
both Western blot analyses and immunofluorescence; ii)
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Figure 3. Immunostaining of occludin in RBE4.B brain capillary endothelial
cells, cultured for 5 days with both cortical neurons and astrocytes, and then
also treated for 24 h with either control serum (a) or SPMS (b). Cells were
immunostained with goat polyclonal anti-occludin N19 antibody, as
described in Materials and methods.
Figure 4. Western blot analysis of total lysates from RBE4.B brain capillary
endothelial cells, cultured for 5 days with both cortical neurons and astrocytes,
and then also treated for 24 h with either control serum (CS) or SPMS serum
(MS). Proteins were immunostained with goat polyclonal anti-occludin N19
antibodies.
Figure 5. Transendothelial electrical resistence (TEER) of endothelial cell
layers co-cultured for 5 days with neurons and astrocytes and then also
treated for 24 h with either control serum (CS) or SPMS serum (MS). The
grey bars represent means of 7 different experiments. Standard deviations
are also shown (black bars). The difference between the means was highly
significant (p<0.005).
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TEER was significantly reduced respect to controls, when the
BBB model was treated with SPMS serum.
These findings are in agreement with the fact that, in
certain clinical studies of MS, leakage into the serum of brain
proteins has been reported, thus suggesting BBB disruption
(32,33).
On the other hand, the fact that the SPMS serum has
a direct damaging effect on isolated neurons is of high
importance since it suggests that neuronal damage in MS
could be a primary event and not only secondary to myelin
damage, as generally assumed (7,8).
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